Balentine LLC’s United Therapeutics UTHR Stock Holding History

Balentine LLC’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-116	Closed	-$11K	–	957
2020 Q1	$11K	Buy	+116	New	+$11K	﹤0.01%	359

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balentine LLC's UTHR Position: Q2 2020 in Review

Balentine LLC sold out of United Therapeutics (UTHR) in Q2 2020, closing a stake of 116 shares — an estimated $11K sold.

Balentine LLC first reported a position in UTHR in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 349 funds tracked by Wall St. Rank hold UTHR as of Q2 2020.

Balentine LLC reported no remaining United Therapeutics position as of Q2 2020 after selling out during the quarter.
Balentine LLC sold 116 United Therapeutics shares in Q2 2020, an estimated $11K.
Balentine LLC first reported a position in United Therapeutics in Q1 2020 and held it in 1 quarter.
Balentine LLC's United Therapeutics position peaked at $11K in Q1 2020.
349 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2020.

Based on Balentine LLC's 13F filing for Q2 2020, filed 14 Aug 2020.